Circadian Variations in Natural Coagulation Inhibitors Protein C, Protein S and Antithrombin in Healthy Men: A Possible Association with Interleukin-6

Summary

Recent observations describe an increase in platelet aggregability and a decrease in fibrinolytic activity in the early morning hours. To determine whether anticoagulant proteins also show such a circadian variation we measured protein C (PC), protein S (PS), antithrombin (AT) and heparin cofactor-II (HC-II) levels on venous plasma samples taken from 10 healthy men at three-hour intervals throughout a 24-hour period. To investigate the possible temporal mapping of circadian periodicity, we also measured plasma levels of beta-thromboglobulin (β-TG) as an indicator of platelet activation, and interleukin-6 (IL-6) as one of the possible regulatory factors that drive this rhythm.

Blood samples were drawn at 6 a.m., 9 a.m., noon, 3 p.m., 6 p.m., 9 p.m. and midnight. PC, IL-6 and β-TG were measured by ELISA, PS and AT by latex immune assay and HC-II by chromogenic substrate method. A significant circadian variation was found in PC, PS, AT, β-TG and IL-6, but not in HC-II levels. PC, PS, IL-6 and β-TG were at their peaks at 6 a.m., and nadirs at a time from noon to midnight. AT peak was at 6 p.m. and nadir at noon. The regression of PS on IL-6 was significant. Although the fluctuations of PS and AT were within the normal ranges during the day, some PC levels of two subjects were below the lower normal limit (0.70).

These data indicate that PC, PS, and AT show a marked circadian periodicity as the other components of the blood coagulation and fibrinolytic system do. The similar trends in plasma concentrations of PC, PS, β-TG and IL-6 may be coincidental, but could reflect a common regulatory mechanism or an effect on each other. The clinical implications of these physiological changes in coagulation inhibitors and the role of IL-6 in the anticoagulant response deserve further studies.

• References

• 1 Muller JE, Tofler GH, Stone PH. Circadian variation and triggers of onset of acute cardiovascular disease. Circulation 1989; 79: 733-43.
• 2 Tofler GH, Brezinski D, Schafer AI, Czeisler CA, Rutherford JD, Willich SN, Gleason RE, Williams G, Muller JE. Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden cardiac death. N Engl J Med 1987; 316: 1514-8.
• 3 Ündar L, Türkay C, Korkmaz L. Circadian variation in circulating platelet aggregates. Ann Med 1989; 21: 429-33.
• 4 Ündar B, Akkoç N, Alakavuklar MN, Çehreli C, Ündar L. Flow cytometric analysis of circadian changes in platelet activation using anti-GMP-140 (P-selectin) monoclonal antibody. Br J Haematol 1996; 93 (02) Suppl 179 (abstract).
• 5 Andreotti F, Kluft C. Circadian variation of fibrinolytic activity in blood. Chronobiol Int 1991; 8: 336-51.
• 6 Akiyama Y, Kazama M, Tahara C, Shimazu C, Otake J, Kamei K, Nakatake T, Sakurai N, Yasumuro Y, Suzuki S, Maeba E, Nishida T. Reference values of haemostasis related factors of healthy Japanese adults. I: Circadian fluctuation. Thromb Res 1990; 60: 281-9.
• 7 Haus E, Cusulos M, Sackett-Lundeen L, Swoyer J. Circadian variations in blood coagulation parameters, alpha-antitrypsin antigen and platelet aggregation and retention in clinically healthy subjects. Chronobiol Int 1990; 7: 203-16.
• 8 Petralito A, Mangiafico RA, Gibiino S, Cuffari MA, Fiore CE. Daily modifications of plasma fibrinogen, platelets aggregation, Howell’s time, PTT, TT and antithrombin III in normal subjects and in patients with vascular disease. Chronobiologia 1982; 9: 195-201.
• 9 Casale G, Butte M, Pasotti C, Ravecca D, de Nikola P. Antithrombin III and circadian rhythms in the aged and in myocardial infarction. Haematologica 1983; 68: 615-9.
• 10 Pechan J, Mikulecky M, Okrucka A. Circadian rhythm of plasma beta-thromboglobulin in healthy human subjects. Blood Coag Fibrinol 1992; 3: 105-7.
• 11 Heeb MJ, Griffin JH. Physiologic inhibition of human activated protein C by α1-antitrypsn. J Biol Chem 1998; 263: 11613-6.
• 12 Dahlback B. Protein S and C4b-binding protein: components involved in the regulation of the protein C anticoagulant system. Thromb Haemost 1991; 66: 49-61.
• 13 Oleksowics I, Mrowiec Z, Zuckerman D, Isaacs R, Dutcher J, Puszin E. Platelet activation induced by interleukin-6: Evidence for a mechanism involving arachidonic acid metabolism. Thromb Haemost 1994; 72: 302-8.
• 14 Andus T, Bauer J, Gerok W. Effects of cytokines on the liver. Hepatology 1991; 13: 364-75.
• 15 Pabinger I, Allaart F, Hermans J, Briet E, Bertina RM. and the Protein C Transmitter Study Group. Hereditary protein C-deficiency: laboratory values in transmitters and guidelines for the diagnostic procedure. Report on a study of the SSC subcommittee on protein C and protein S. Thromb Haemost 1992; 68: 470-4.
• 16 Krulder JWM, de Boer A, van den Besselaar AMHP, Cohen AF, Schoemaker HC, Briet E, Meinders AE. Diurnal rhythm in anticoagulant effect of heparin during a low dose constant rate infusion. A study in healthy volunteers. Thromb Haemost 1992; 68: 30-2.
• 17 Wu KK, Folsom AR, Heiss G, Davis CE, Conlan MG, Barnes R. Association of coagulation factors and inhibitors with carotid arterial atherosclerosis. Early results of the ARIC study. Ann Epidemiol 1992; 2: 471-80.
• 18 Vigano S, Mannucci PM, D’Angelo A, Gelfi C, Gensini GF, Rostagno C, Serneri GGN. Protein C antigen is not an acute phase reactant and is often high in ischemic heart disease and diabetes. Thromb Haemost. 1984; 52: 263-6.
• 19 Vaziri ND et al. Coagulation, fibrinolytic and inhibitory proteins in acute myocardial infarction and angina pectoris. Am J Med 1992; 93: 651-7.
• 20 Stene M, Paragiotis N, Tuck ML, Sowers JR, Mayes D, Berg G. Plasma norepinephrin levels are influenced by sodium intake, glucocorticoid administration and circadian changes in normal man. J Clin Endocrinol Metab 1980; 51: 1340-5.
• 21 Muller JE, Tofler GH, Verrier RL. Sympathetic activity as the cause of the morning increase in cardiac events: A likely culprit but the evidence remains circumstantial. Circulation 1995; 91: 2508-10.
• 22 LeMay LG, Vander AJ, Kluger MJ. The effects of psychological stress on plasma interleukin-6 activity in rats. Physiol Behav 1990; 47: 957-61.
• 23 Brett J, Steinberg S, deGroot P, Nawroth P, Stern D. Norepinephrine down-regulates the activity of protein S on endothelial cells. J Cell Biol 1988; 106: 2109-19.
• 24 Rumley A, Lowe GDO, Lee AJ, Crilly A, Madhok R, Tunstall-Pedoe H. Correlation of plasma fibrinogen, plasminogen activator inhibitor, and red cell aggregation with interleukin-6 levels in a population study. Blood Coag Fibrinol 1993; 4: 382 (abstract).
• 25 van Deventer SJG, Büller HR, ten Cate JW, Aarden LA, Hack CE, Sturk A. Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood 1990 76: 2520-6.
• 26 Hooper WC, Phillips DJ, Ribeiro M, Benson J, Evatt BL. IL-6 upregulates protein S expression in the HepG-2 hepatoma cells. Thromb Haemost 1995; 73: 819-24.
• 27 Hooper WC, Phillips DJ, Evatt BL. Endothelial cell protein S synthesis is upregulated by the complex of IL-6 and soluble IL-6 receptor. Thromb Haemost 1997; 77: 1014-9.
• 28 Niessen RWLM, Lamping RJ, Jansen PM, Prins MH, Peters M, Taylor Jr FB, de Vijlder JJM, ten Cate JW, Hack CE, Sturk A. Antithrombin acts as a negative acute phase protein as established with studies on HepG2 cells and in Baboons. Thromb Haemost 1997; 78: 1088-92.
• 29 Koike C, Hayakawa Y, Niiya K, Sakuragawa N. The production of heparin cofactor II is not regulated by inflammatory cytokines in human hepatoma cells: Comparison with plasminogen activator inhibitor type-1. Thromb Haemost 1996; 75: 298-302.
• 30 Gray E, Thomas S, Mistry Y, Poole S. Inhibition of tissue factor and cytokine release. Haemostasis 1996; 26 (Suppl. 01) (suppl) 92-5.